Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course

详细信息	查看全文 | 推荐本文 |

• 作者：Ulrike Bacher^a ; Wolfgang Kern^b ; Tamara Alpermann^b ; Susanne Schnittger^b ; Claudia Haferlach^b ; Torsten Haferlach^b ; ^{torsten.haferlach@mll.com}
• 关键词：Ring sideroblasts ; Myelodysplastic syndromes (MDS) ; Cytomorphology ; Cytogenetics ; Classification ; International Prognostic Scoring System (IPSS)
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：July, 2012
• 卷：36
• 期：7
• 页码：826-831
• 文件大小：458 K

摘要

In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts 鈮?5%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p < 0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.